web_fetch Read a news article as markdown
A press release found by news_search, served from the cache with its author, publisher, publication time and the crawl that discovered it.
{
"urls": [
"https://www.biospace.com/press-releases/exthymic-secures-up-to-25m-arpa-h-contract-to-enable-hospital-based-cell-therapy-production-prototype"
],
"maxCharacters": 1500
}{
"results": [
{
"url": "https://www.biospace.com/press-releases/exthymic-secures-up-to-25m-arpa-h-contract-to-enable-hospital-based-cell-therapy-production-prototype",
"markdown": "SAN DIEGO--(BUSINESS WIRE)--Exthymic Corporation (Exthymic) today announced that the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, has awarded Exthymic a contract to develop a cell therapy device to address key issues underlying patient access and affordability.\n\nThe ARPA-H Scalable Cell Therapies through Optimized Phenotyping and Enrichment (SCOPE) project will provide Exthymic with up to $25 million of funding over two years to develop and test LITTLESTAR, a next generation device that enables the safe, reliable production of engineered cell therapies like CAR-T cell therapy by managing patient variability during the production process.\n\n*Using a patient's own cells is what makes cell therapies powerful. It's also what makes them so hard to produce,\"* says Rich Stoner, Exthymic CEO*. \"The industry has spent a decade optimizing production, but it still can't tell you what makes one patient's cells work and another's fail. So it settles for a process it can get approved, and then decides which patients that process will accept. We won't solve access or scale commercially that way. Simply put, we're failing patients.\"*\n\nThe LITTLESTAR device functions by directly measuring and reacting to differences in cell phenotype over a full production process. This adaptive control ensures each final dose is produced safely and reliably without the overhead of a dedicated clean room or quality control laboratory,",
"truncated": true,
"version": {
"no": 1,
"firstSeenAt": "2026-10-05T15:50:53.368246060Z",
"lastSeenAt": "2026-10-05T15:50:53.368246060Z",
"isLatest": true,
"totalVersions": 1,
"contentHash": "45ae47750ef11fff18e07732d689e1663c057dae3542c2c7b780998920dd1304"
},
"metadata": {
"title": "Exthymic Secures up to $25M ARPA-H Contract to Enable Hospital-Based Cell Therapy Production Prototype",
"author": "Gabrielle Masson",
"publishedAt": "2026-10-05T13:48:04.298Z",
"publisher": "BioSpace",
"categories": [
"web",
"news"
],
"discoveredVia": "ccnews"
},
"source": "cache"
}
]
}Captured 2026-10-05 17:28 UTC from production